Search Results

You are looking at 121 - 130 of 132 items for :

  • "prognosis" x
Clear All
Open access

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana and Alessia Ciarrocchi

die within 1 year from diagnosis. Well-differentiated papillary thyroid cancers (PTCs) are considered indolent tumors, with slow rate of growth, low metastatic potential and excellent prognosis (10-year patient survival rate up to 95%) ( 4 , 5

Open access

Qianqian Pang, Yuping Xu, Xuan Qi, Yan Jiang, Ou Wang, Mei Li, Xiaoping Xing, Ling Qin and Weibo Xia

cyclooxygenase-2 in non-small cell lung cancer: correlations with angiogenesis and prognosis . Oncology Letters 2014 8 1589 – 1594 . ( https://doi.org/10.3892/ol.2014.2371 ) 25202373 10.3892/ol.2014.2371 17 Tseng-Rogenski S Gee J Ignatoski KW Kunju LP

Open access

J Chycki, A Zajac, M Michalczyk, A Maszczyk and J Langfort

characterization and prognosis of the metabolically healthy obesity phenotype: a systematic review and meta-analysis . Progress in Cardiovascular Diseases 2018 61 . ( https://doi.org/10.1016/j.pcad.2018.07.008 ) 30122522 19 Weaver JU . Classical

Open access

Jaafar Jaafar, Eugenio Fernandez, Heba Alwan and Jacques Philippe

and proliferation ( 9 ). A recent report has found that overexpression of PD-L2 is associated with poorer prognosis in hepatocellular carcinoma ( 10 ) and salivary gland tumors ( 11 ). PD-L1 is highly expressed by certain tumor cells in the tumor

Open access

T P McVeigh, R J Mulligan, U M McVeigh, P W Owens, N Miller, M Bell, F Sebag, C Guerin, D S Quill, J B Weidhaas, M J Kerin and A J Lowery

. Studying genetic variations in cancer prognosis (and risk): a primer for clinicians. Oncologist 2009 14 657 – 666 . ( doi:10.1634/theoncologist.2009-0042 ) 10.1634/theoncologist.2009-0042 24 Jazdzewski K Murray EL Franssila K Jarzab

Open access

Qiu-ming Yao, Bin Wang, Xiao-fei An, Jin-an Zhang and Liumei Ding

Makepeace A Lim EM Yeap BB Peters KE Davis TM. Prevalence and prognosis of a low serum testosterone in men with type 2 diabetes: the Fremantle Diabetes Study Phase II . Clinical Endocrinology 2016 85 444 – 452 . ( https://doi.org/10.1111/cen.13087

Open access

Doron Weinstein, Rive Sarfstein, Zvi Laron and Haim Werner

in the rates of insulin secretion have been shown to influence cancer risk and prognosis among individual patients (21) . In contrast to our results, Heidegger et al . (3) showed that PC3 and LNCaP cells express both IGF1R and INSR and that IGF1

Open access

Cleofas Marcial-Medina, Alejandra Ordoñez-Moreno, Christian Gonzalez-Reyes, Pedro Cortes-Reynosa and Eduardo Perez Salazar

prognosis of breast cancer . Obesity Reviews 2006 7 333 – 340 . ( https://doi.org/10.1111/j.1467-789X.2006.00261.x ) 10.1111/j.1467-789X.2006.00261.x 3 Xue F Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current

Open access

Renea A Taylor, Jennifer Lo, Natasha Ascui and Matthew J Watt

transforming growth factor-β (TGF-β) superfamily, predicts poor prostate cancer prognosis (46) by mediating the interaction between macrophages and prostate cancer development (47) . In addition, other pro-inflammatory cytokines such as IL-8 (48, 49) and

Open access

Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer and Irvin M Modlin

response to PRRT and determining prognosis. There are a number of different national and societal neuroendocrine guidelines that variably evaluate the usage of biomarkers and imaging (North American – NANETs, National Comprehensive Cancer Network – NCCN